TrendFlares logo

Lumos Pharma, Inc. (LUMO)

$3.92 5.95% $0.22 Healthcare

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

$31.85M

Mr. Richard J. Hawkins

32.00

Austin, TX

Nov 11, 2011

-0.89

$-4.42

3.40

4.23

-2,405.72%

-0.88

-0.04

3.06

21.21

4.23

-167.40%

-157.99%

Neutral

Similar stocks (9)

Erasca, Inc.

ERAS

$2.97 2.77%
Uptrend

Eliem Therapeutics, Inc.

ELYM

$8.28 3.76%
Uptrend

Rezolute, Inc.

RZLT

$4.82 -1.03%
Uptrend

Shattuck Labs, Inc.

STTK

$3.70 1.37%
Downtrend

Century Therapeutics, Inc.

IPSC

$1.70 3.03%
Downtrend

Champions Oncology, Inc.

CSBR

$4.89 14.25%
Downtrend

Anebulo Pharmaceuticals, Inc.

ANEB

$2.08 4.00%
Downtrend

Forte Biosciences, Inc.

FBRX

$7.00 4.09%
Downtrend

Silo Pharma, Inc.

SILO

$1.06 3.92%
Downtrend

ETF Exposure (8)

Dimensional U.S. Equity ETF

DFUS

1.2177e-4%

$61.75 1.80%
Uptrend

Vanguard Extended Market Index Fund Institutional Shares

VIEIX

0%

$138.77 2.02%
Uptrend

Vanguard Institutional Total Stock Market Index Fund Institutional Shares

VITNX

0%

$97.80 1.74%
Uptrend

Vanguard Institutional Total Stock Market Index Fund

VITPX

0%

$97.78 1.74%
Uptrend

Vanguard Total Stock Market Index Fund

VITSX

0%

$137.33 1.73%
Uptrend

Vanguard Total Stock Market Index Fund

VTI

0%

$282.05 1.69%
Uptrend

Vanguard Total Stock Market Index Fund

VTSAX

0%

$137.30 1.73%
Uptrend

Vanguard Extended Market Index Fund

VXF

0%

$182.92 2.00%
Uptrend